Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: LarryS who wrote (10890)	7/23/1999 10:04:00 AM
From: aknahow	Read Replies (3) \| Respond to of 17367

Minor point but AGN did not get I-PREX. They obtained rights only to use BPI in conjunction with other antibiotics. XOMA kept the rights to all other properties of I-Prex for the eye. One can read this anyway they want. I read it as XOMA was unable to convince AGN to pay the full price for all the properties and decided to cut the deal anyway for limited use. You are probably right as there is so much time involved before they even get to clinical trials.